Literature DB >> 19451418

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Martin J van den Bent1, Michael A Vogelbaum, Patrick Y Wen, David R Macdonald, Susan M Chang.   

Abstract

Recent trials in glioma have revealed significant limitations in the end points used. This requires a critical and comprehensive review of how brain tumor trials are conducted, particularly of which end points are defined and how response and progression are defined.

Entities:  

Mesh：

Year:  2009        PMID： 19451418      PMCID： PMC2702230          DOI： 10.1200/JCO.2009.22.4998

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  38 in total

Review 1.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

Authors:  M C Y de Wit; H G de Bruin; W Eijkenboom; P A E Sillevis Smitt; M J van den Bent
Journal:  Neurology       Date:  2004-08-10       Impact factor: 9.910

2.  Steroid-induced CT changes in patients with recurrent malignant glioma.

Authors:  J G Cairncross; D R Macdonald; J H Pexman; F J Ives
Journal:  Neurology       Date:  1988-05       Impact factor: 9.910

3.  MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.

Authors:  F W Floeth; A Aulich; K J Langen; K J Burger; W J Bock; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

4.  Postoperative contrast enhancement in patients with brain tumor.

Authors:  J G Cairncross; J H Pexman; M P Rathbone; R F DelMaestro
Journal:  Ann Neurol       Date:  1985-06       Impact factor: 10.422

5.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

Authors:  E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  Continuous growth of mean tumor diameter in a subset of grade II gliomas.

Authors:  Emmanuel Mandonnet; Jean-Yves Delattre; Marie-Laure Tanguy; Kristin R Swanson; Antoine F Carpentier; Hugues Duffau; Philippe Cornu; Rémy Van Effenterre; Ellsworth C Alvord; Laurent Capelle
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

7.  CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience.

Authors:  Maria G Matheus; Mauricio Castillo; Matthew Ewend; Jeffrey K Smith; Lester Knock; Sharon Cush; David E Morris
Journal:  AJNR Am J Neuroradiol       Date:  2004-08       Impact factor: 3.825

8.  Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.

Authors:  M Brada; L Viviers; C Abson; F Hines; J Britton; S Ashley; S Sardell; D Traish; A Gonsalves; P Wilkins; C Westbury
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

9.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.

Authors:  K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

Review 10.  Response criteria for glioma.

Authors:  A Gregory Sorensen; Tracy T Batchelor; Patrick Y Wen; Wei-Ting Zhang; Rakesh K Jain
Journal:  Nat Clin Pract Oncol       Date:  2008-08-19
View more
  108 in total

1.  Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.

Authors:  Alexander Radbruch; Kira Lutz; Benedikt Wiestler; Philipp Bäumer; Sabine Heiland; Wolfgang Wick; Martin Bendszus
Journal:  Neuro Oncol       Date:  2011-12-06       Impact factor: 12.300

2.  Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Authors:  Radhika Srinivasan; Joanna J Phillips; Scott R Vandenberg; Mei-Yin C Polley; Gabriela Bourne; Alvin Au; Andrea Pirzkall; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-07-20       Impact factor: 12.300

3.  Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Authors:  Fabio M Iwamoto; Andreas F Hottinger; Sasan Karimi; Elyn Riedel; Jocelynn Dantis; Maryam Jahdi; Katherine S Panageas; Andrew B Lassman; Lauren E Abrey; Martin Fleisher; Lisa M DeAngelis; Eric C Holland; Adília Hormigo
Journal:  Neuro Oncol       Date:  2011-08-10       Impact factor: 12.300

4.  Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.

Authors:  Inas S Khayal; Mei-Yin C Polley; Llewellyn Jalbert; Adam Elkhaled; Susan M Chang; Soonmee Cha; Nicholas A Butowski; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-05-25       Impact factor: 12.300

5.  Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.

Authors:  Emma Essock-Burns; Janine M Lupo; Soonmee Cha; Mei-Yin Polley; Nicholas A Butowski; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-10-29       Impact factor: 12.300

6.  MRI and thallium-201 SPECT in the prediction of survival in glioma.

Authors:  Maaike J Vos; Johannes Berkhof; Otto S Hoekstra; Ingeborg Bosma; Eefje M Sizoo; Jan J Heimans; Jaap C Reijneveld; Esther Sanchez; Frank J Lagerwaard; Jan Buter; David P Noske; Tjeerd J Postma
Journal:  Neuroradiology       Date:  2011-07-14       Impact factor: 2.804

Review 7.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

8.  Quantitative tumor segmentation for evaluation of extent of glioblastoma resection to facilitate multisite clinical trials.

Authors:  James S Cordova; Eduard Schreibmann; Costas G Hadjipanayis; Ying Guo; Hui-Kuo G Shu; Hyunsuk Shim; Chad A Holder
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

9.  A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.

Authors:  Darren Hargrave; Birgit Geoerger; Didier Frappaz; Torsten Pietsch; Lyle Gesner; Laura Cisar; Aurora Breazna; Andrew Dorman; Ofelia Cruz-Martinez; Jose Luis Fuster; Xavier Rialland; Céline Icher; Pierre Leblond; David Ashley; Giorgio Perilongo; Martin Elliott; Martin English; Niels Clausen; Jacques Grill
Journal:  J Neurooncol       Date:  2013-03-04       Impact factor: 4.130

10.  Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 Tesla for characterization of differences in metabolite levels.

Authors:  Yan Li; Peder Larson; Albert P Chen; Janine M Lupo; Eugene Ozhinsky; Douglas Kelley; Susan M Chang; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2014-06-17       Impact factor: 4.813
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.